Pharmaceuticals, Biotechnology and Life Sciences
Biocartis Group said on Wednesday that on the day before, July 11, 2017 the US FDA published a final list of devices that it has exempted from 510(k) premarket notification requirements in accordance with the US 21st Century Cures Act (signed into US law 13 December 2016).
Omya said Wednesday it will showcase its Omyapharm multifunctional excipient platform based on functionalized calcium carbonate, a highly structured mineral At CPhI in Frankfurt.
Gelesis Inc, a subsidiary of PureTech Health, has completed treatment of the final patient in the pivotal GLOW (Gelesis Loss Of Weight) Study, to assess the long-term efficacy and safety of its Gelesis100.
Boehringer Ingelheim has reported that final results from RE-VERSE AD study showed that idarucizumab, marketed in the U.S. as Praxbind, was able to immediately reverse the anticoagulant effect of Pradaxa (dabigatran etexilate mesylate) in patients in emergency situations.
Evgen Pharma said Tuesday that its lead product, SFX-01, will be tested against triple negative breast cancer (TNBC) in new preclinical research at the Manchester Cancer Research Centre, UK.
Sanofi announced today it will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut in the United States.
Norwegian pharmaceutical company Vistin Pharma ASA has entered a Sales and Purchase agreement with independently-owned Australian company TPI Enterprises Limited for its opioids and tablet manufacturing business.
Guerbet, the global specialist in contrast products and solutions for medical imaging, will phase out sales throughout the world of two products: Hexabrix (meglumine and sodium ioxaglate) and Optimark (gadoversetamide).
BioInvent International and ThromboGenics have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317.
Celgene Corporation and BeiGene have entered into a strategic collaboration to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1…